SCHEMBL31104171

SCHEMBL31104171

Cc1c(CCCO)cnn(C2CCCCO2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.40
▸ POLB P06746 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP4F2 P78329 4/20 0.39
▸ CYP4A11 Q02928 4/20 0.39
▸ RXRA P19793 1/20 0.37
▸ RXRB P28702 1/20 0.37
▸ RXRG P48443 1/20 0.37
▸ GAA P10253 1/20 0.34
▸ PDE1A P54750 1/20 0.34
▸ PDE1B Q01064 1/20 0.34
▸ PDE1C Q14123 1/20 0.34
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ DRD1 P21728 1/20 0.32
▸ ATR Q13535 1/20 0.32
▸ KDM5B Q9UGL1 1/20 0.32
▸ FGFR1 P11362 1/20 0.31
▸ FGFR2 P21802 1/20 0.31
▸ FGFR4 P22455 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31103919 0.88 ALDH1A1 (0.40) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL31104026 0.86 ALDH1A1 (0.40) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL31104342 0.83 ALDH1A1 (0.38) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL31104287 0.82 ALDH1A1 (0.36) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL25341195 0.82 RXRA (0.42) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL31104035 0.81 ALDH1A1 (0.38) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL25342107 0.81 ALDH1A1 (0.40) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL31386712 0.78 ALDH1A1 (0.41) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL31386650 0.76 CYP4F2 (0.35) ALDH1A1POLBLMNACYP4F2CYP4A11
SCHEMBL15666220 0.76 ALDH1A1 (0.46) ALDH1A1POLBLMNACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 — — US disclosed
WO-2024182693-A1 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER VIVIDION THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 STAT3, JAK2, STAT1 ALDH1A1 2652/4885POLB 3690/4885LMNA 4098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback